Compare VSECU & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSECU | AGIO |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | 1400 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 2013 |
| Metric | VSECU | AGIO |
|---|---|---|
| Price | $48.12 | $29.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $37.63 |
| AVG Volume (30 Days) | 13.5K | ★ 623.7K |
| Earning Date | N/A | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $71.05 |
| Revenue Next Year | N/A | $163.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.90 | $22.24 |
| 52 Week High | $58.93 | $46.00 |
| Indicator | VSECU | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.52 | 59.42 |
| Support Level | N/A | $26.48 |
| Resistance Level | $57.23 | $30.90 |
| Average True Range (ATR) | 0.95 | 0.97 |
| MACD | -0.70 | 0.06 |
| Stochastic Oscillator | 21.97 | 82.43 |
VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.